HDAC Activity in Peripheral Skeletal Muscle in COPD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Polkey, Imperial College London
ClinicalTrials.gov Identifier:
NCT00180752
First received: September 13, 2005
Last updated: February 17, 2016
Last verified: August 2008

September 13, 2005
February 17, 2016
September 2005
August 2008   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00180752 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
HDAC Activity in Peripheral Skeletal Muscle in COPD
The Investigation of HDAC and NF Kappa B Activity in Peripheral Skeletal Muscle in COPD
We wish to study the effect of Chronic Obstructive Pulmonary Disease on the activity of the nuclear transcription pathway in peripheral skeletal muscle to determine whether altered activity of this pathway may be responsible for the muscle dysfunction observed in these patients.
Peripheral muscle dysfunction is well recognised in COPD. We wish to study patients who we have found to have weak quadriceps muscles and study the molecular mechanisms underlying this problem. Patients will be well characterised with regard to their physiologic parameters and quadriceps muscle biopsies will be taken. These biopsy samples will be analysed with respect to NFkappaB activity and HDAC activity by nuclear extraction and for muscle inflammatory cytokines. We know that in the lung tissue of COPD patients there is evidence of a reduction in HDAC activity which might be responsible for the higher levels of pronflammatory cytokines in the lung. We will also study a healthy control group and a small selection of patients who are in respiratory failure due to idiopathic scoliosis in the same way.
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:
Plasma and serum samples, quadriceps muscle specimens
Probability Sample
COPD patients and healthy age-and sex-matched controls
COPD
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
August 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

COPD

Exclusion Criteria:

Aspirin therapy Bleeding diasthesis Neuromuscular disease

Both
40 Years to 85 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00180752
MusHDAC -1
No
No
Not Provided
Michael Polkey, Imperial College London
Imperial College London
Not Provided
Principal Investigator: Michael I Polkey, PhD Royal Brompton & Harefield NHS Foundation Trust
Imperial College London
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP